Monopar Therapeutics (NASDAQ:MNPR) Releases Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Monopar Therapeutics (NASDAQ:MNPR) issued its quarterly earnings data on Thursday. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.10, FiscalAI reports.

Monopar Therapeutics Trading Up 1.9%

Shares of MNPR traded up $1.33 during trading hours on Thursday, reaching $73.06. 217,522 shares of the stock traded hands, compared to its average volume of 202,799. Monopar Therapeutics has a 52-week low of $50.07 and a 52-week high of $124.82. The company’s 50-day moving average price is $84.40 and its two-hundred day moving average price is $77.39. The company has a market cap of $490.38 million, a P/E ratio of -33.64 and a beta of 1.62.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MNPR. BTIG Research lifted their target price on Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. Wall Street Zen cut Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. UBS Group set a $125.00 price objective on Monopar Therapeutics in a research note on Thursday, July 23rd. Finally, HC Wainwright boosted their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $122.78.

Insider Activity

In other Monopar Therapeutics news, Director Christopher Starr sold 8,400 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $78.50, for a total transaction of $659,400.00. Following the sale, the director directly owned 5,173 shares of the company’s stock, valued at $406,080.50. This trade represents a 61.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim Tsuchimoto sold 4,090 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total value of $455,585.10. Following the sale, the director directly owned 7,396 shares in the company, valued at approximately $823,840.44. This represents a 35.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 51,920 shares of company stock worth $4,527,913. 9.70% of the stock is currently owned by corporate insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.